Godavari Drugs Peer Comparison

BSE: 530317

₹98.87

₹2.07 (2.14%)

As on 03-Sep-2026IST

Market cap

₹108 Cr

Revenue (TTM)

₹110 Cr

P/E Ratio

26

P/B Ratio

1.4

Div. Yield

0 %

Edit

	Godavari Drugs	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Market cap (₹ Cr)	108	21,256	21,609	18,069	17,367
Revenue (₹ Cr)	110	2,570	2,287	3,230	2,432
Net Profit (₹ Cr)	4.16	735.15	678.07	666.92	169.62
Net Margin (%)	3.75	26.88	28.10	20.60	6.90
RoE (%)	6.41	19.16	19.73	18.75	20.76
Price to Earnings	25.96	28.91	32.48	28.06	102.39
Price-To-Book	1.37	4.82	5.74	4.47	19.21

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Godavari Drugs	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Operating Revenue	109.95	2,569.77	2,287.33	3,229.67	2,432.06
Total Income	110.90	2,735.39	2,413.29	3,237.12	2,458.54
Total Expenditure	100.03	1,628.14	1,490.75	2,090.06	2,202.20
EBITDA	9.93	941.63	796.58	1,139.61	229.86
Depreciation	2.42	57.58	78.10	281.06	17.24
EBIT	7.51	884.05	718.48	858.55	212.62
Interest	3.87	7.69	0.88	190.64	5.72
Other Income	0.94	165.62	125.96	7.45	26.48
Exceptional Items	0.36	-49.16	0.00	-17.24	-5.13
Profit before Tax	4.94	992.82	843.56	658.12	228.25
Provision for Tax	0.78	257.67	165.49	-8.80	58.63
Profit after Tax	4.16	735.15	678.07	666.92	169.62

Liabilities (₹ Cr)

	Godavari Drugs	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Shareholder's Funds	75.80	4,202.90	3,586.42	3,902.67	872.79
Minority Interest	0.00	0.00	-12.71	-21.81	0.00
Non-Current Liabilities	39.49	91.50	28.74	1,392.75	134.50
Current Liabilities	85.14	627.48	385.94	2,077.10	981.81
Total Liabilities	143.08	4,911.11	3,207.85	6,865.52	1,879.19

Assets (₹ Cr)

	Godavari Drugs	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Non-Current Assets	86.85	770.28	1,291.22	5,617.77	42.47
Current Assets	111.80	3,803.22	2,585.66	1,539.85	1,739.93
Total Assets	143.08	4,911.11	3,207.85	6,865.52	1,879.19
Total Debt*	64.35	2.50	0.55	2,421.66	0.00
Net Current Assets	26.65	3,175.74	2,199.72	-537.25	758.12
Contingent Liabilities	0.50	363.79	0.64	51.96	98.41

Cashflow (₹ Cr)

	Godavari Drugs	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Cash From Operating Activities	11.20	659.75	432.37	1,065.01	65.36
Cash Flow from Investing Activities	-19.51	-71.34	-334.73	-79.97	30.80
Cash from Financing Activities	8.07	-205.34	-38.32	-881.32	-65.59
Net Cash Inflow / Outflow	-0.25	383.07	59.32	103.72	30.57

Ratios

Profitability Ratios

	Godavari Drugs	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
ROCE (%)	10.13	26.21	26.22	13.59	21.29
ROE (%)	6.41	19.16	19.73	18.75	20.76
ROA (%)	2.42	14.95	18.69	9.26	9.67
EBIT Margin (%)	6.83	34.40	31.41	26.58	8.74
Net Margin (%)	3.75	26.88	28.10	20.60	6.90
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Godavari Drugs	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Revenue Growth (%)	4.76	10.69	15.01	9.59	31.10
EBIT Growth (%)	-16.51	24.14	18.45	16.84	-12.99
Net Profit Growth (%)	9.69	-9.09	19.61	62.68	-7.49
EPS Growth (%)	-13.09	14.40	17.73	67.41	-18.33
Book Value Growth (%)	11.24	17.30	23.77	10.19	7.70

Valuation Ratios

	Godavari Drugs	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Price / Earnings	22.61	27.55	32.48	27.38	100.08
Price / Book Value	1.37	4.82	5.74	4.47	19.21
Dividend Yield (%)	0.00	1.61	0.14	0.55	0.52
EV/EBITDA	17.11	19.27	26.44	17.82	73.60
Market Cap (₹ Cr)	65.86	18,318.10	15,219.80	19,292.77	21,515.93

Solvency Ratios

	Godavari Drugs	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Debt to Equity	0.49	0.00	0.00	0.24	0.00
Short term debt to equity ratio	0.87	0.00	0.00	0.14	--
Current Ratio	1.31	6.06	6.70	0.74	1.77
Quick Ratio	0.77	5.31	5.59	0.53	0.73
Interest Coverage	2.28	130.11	959.59	4.45	40.90

Operating Efficiency Ratios

	Godavari Drugs	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Debtors to sales (%)	39.64	7.07	36.10	21.07	8.79
Asset Turnover	0.64	0.52	0.63	0.45	1.39
Receivable days	163.82	29.10	110.70	54.06	35.81
Inventory Days	78.24	69.53	65.86	32.16	82.25
Payable days	134.84	76.77	105.88	140.91	124.39
Cash Conversion Cycle	107.21	21.86	70.68	-54.69	-6.33

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly